These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 21840248)

  • 1. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors.
    Coleman K
    Curr Opin Microbiol; 2011 Oct; 14(5):550-5. PubMed ID: 21840248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New β-lactam-β-lactamase inhibitor combinations in clinical development.
    Shlaes DM
    Ann N Y Acad Sci; 2013 Jan; 1277():105-14. PubMed ID: 23346860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
    Weston GS; Blázquez J; Baquero F; Shoichet BK
    J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new in antibiotic resistance? Focus on beta-lactamases.
    Babic M; Hujer AM; Bonomo RA
    Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams.
    Neu HC
    Curr Clin Top Infect Dis; 1987; 8():37-61. PubMed ID: 3077281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of beta-lactamase-producing pathogens.
    Acar JF; Kitzis MD; Gutmann L
    APMIS Suppl; 1989; 5():2-8. PubMed ID: 2660867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience.
    Wilson SE; Nord CE
    Am J Surg; 1995 May; 169(5A Suppl):21S-26S. PubMed ID: 7755164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanisms of resistance to beta-lactam inhibitors of beta-lactamases].
    Blázquez J
    Rev Esp Quimioter; 1998 Dec; 11(4):368-9. PubMed ID: 10336318
    [No Abstract]   [Full Text] [Related]  

  • 11. [Re-evaluation of the gastrointestinal effects of beta-lactam inhibitors of beta-lactamase].
    Sábada B
    Rev Esp Quimioter; 1998 Dec; 11(4):377-9. PubMed ID: 10336322
    [No Abstract]   [Full Text] [Related]  

  • 12. An animal farm called extended-spectrum beta-lactamase: antimicrobial resistance as a zoonosis.
    Pappas G
    Clin Microbiol Infect; 2011 Jun; 17(6):797-8. PubMed ID: 21463398
    [No Abstract]   [Full Text] [Related]  

  • 13. Engineered Amp C β-lactamase as a fluorescent screening tool for class C β-lactamase inhibitors.
    Tsang MW; Chan PH; So PK; Ma DL; Tsang CW; Wong KY; Leung YC
    Anal Chem; 2011 Mar; 83(6):1996-2004. PubMed ID: 21338058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A concise synthesis of a β-lactamase inhibitor.
    Mangion IK; Ruck RT; Rivera N; Huffman MA; Shevlin M
    Org Lett; 2011 Oct; 13(20):5480-3. PubMed ID: 21916523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.
    Shahid M; Sobia F; Singh A; Malik A; Khan HM; Jonas D; Hawkey PM
    Crit Rev Microbiol; 2009; 35(2):81-108. PubMed ID: 19514910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combinations.
    Buynak JD
    Biochem Pharmacol; 2006 Mar; 71(7):930-40. PubMed ID: 16359643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
    Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
    Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and clinical aspects of beta-lactam antibiotics and beta-lactamases.
    Kotra LP; Mobashery S
    Arch Immunol Ther Exp (Warsz); 1999; 47(4):211-6. PubMed ID: 10483868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
    Papp-Wallace KM; Nguyen NQ; Jacobs MR; Bethel CR; Barnes MD; Kumar V; Bajaksouzian S; Rudin SD; Rather PN; Bhavsar S; Ravikumar T; Deshpande PK; Patil V; Yeole R; Bhagwat SS; Patel MV; van den Akker F; Bonomo RA
    J Med Chem; 2018 May; 61(9):4067-4086. PubMed ID: 29627985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omission of extended spectrum β lactamases detection: are the new Clinical Laboratory Standards Institute guidelines misleading?
    Chande C; Makhija S; Lilani S; Shirpurkar R; Veer P; Chivate A; Patekar P; Joshi A
    Indian J Med Microbiol; 2011; 29(4):443-4. PubMed ID: 22120816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.